This article describes drugs used in primary care that could alter patients' risk for and severity of COVID-19. The risks and benefits of each drug class were differentiated according to the strength of evidence from 58 selected randomized controlled trials, systematic reviews, and meta-analyses. Most of the studies reported on drugs affecting the renin-angiotensin-aldosterone system. Other classes included opioids, acid suppressants, nonsteroidal anti-inflammatory drugs, corticosteroids, vitamins, biguanides, and statins. Current evidence has not fully differentiated drugs that may increase risk versus benefits in COVID-19 infection. Further studies are needed in this area.

本文介绍了初级保健中使用的可能改变患者感染COVID-19的风险和严重程度的药物。根据 58 项选定的随机对照试验、系统评价和荟萃分析的证据强度，区分了每种药物类别的风险和益处。大多数研究报告了影响肾素-血管紧张素-醛固酮系统的药物。其他类别包括阿片类药物、抑酸剂、非甾体类抗炎药、皮质类固醇、维生素、双胍类药物和他汀类药物。目前的证据尚未完全区分可能增加COVID-19感染风险与益处的药物。该领域需要进一步研究。